The Impact of Continuous Glucose Monitoring Use Versus Nonuse on Clinical and Economic Outcomes in Individuals Using Rapid- and Short-Acting Insulin: A Retrospective Analysis
Main finding · Total health care costsResult — go to the resultT test t(698,086) = −71.41Authors' conclusion
These findings reinforce the clinical and economic value of CGM and support recent policy updates expanding access for insulin-treated populations.
Study context
- Population
- Adults with diabetes with ≥1 claim for rapid- or short-acting insulin, January 1, 2010–October 31, 2022, Mariner Commercial Claims Database
- Participants
- 3,139,979 adults
- Exposure
- CGM use vs nonuse
- With CGM (wCGM)n = 536,512
- xCGMn = 2,603,467reference
- Outcome
- Total health care costs
Methodological detailsclaims database, direct matching
- Claims database
- Direct matching
Main finding
As reported in the abstract
T test
t(698,086) = −71.41
P < 0.001
By group
wCGM
$6,245
xCGM
$7,786
Observational data: associations, not effects.
Further findings
Emergency room (ER) days and inpatient (IP) days · 3, 6, 9 and 12 months
- wCGM had significantly fewer ER days and IP days than xCGM at 3, 6, 9 and 12 months
Achieving HbA1c <9%
- Odds of achieving HbA1c <9%, CGM users vs nonusers (19% higher odds)
- OR = 1.19
ER/IP days associated with hypoglycemia, diabetic ketoacidosis (DKA), or both
- Significantly smaller proportion of wCGM than xCGM had ER/IP days associated with hypoglycemia, DKA, or both
Original publication
The Impact of Continuous Glucose Monitoring Use Versus Nonuse on Clinical and Economic Outcomes in Individuals Using Rapid- and Short-Acting Insulin: A Retrospective Analysis. Diabetes Technol Ther. Published 3 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →